Neuropore achieves $5 million (USD) milestone from UCB collaboration

Neuropore announced advancement of UCB0599 to next phase.  UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson’s disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression of Parkinson’s disease can be slowed or halted. UCB0599 belongs to a series of molecules discovered by Neuropore, which were licensed to UCB in 2014 (Press Release)

Be the first to comment

Or sign in with email

    Please check your e-mail for a link to activate your account.